as 09-05-2025 4:00pm EST
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
Founded: | 2006 | Country: | United States |
Employees: | N/A | City: | REDWOOD CITY |
Market Cap: | 66.3M | IPO Year: | 2014 |
Target Price: | $19.75 | AVG Volume (30 days): | 87.6K |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -8.10 | EPS Growth: | N/A |
52 Week Low/High: | $1.78 - $8.56 | Next Earning Date: | 11-03-2025 |
Revenue: | $1,000,000 | Revenue Growth: | -72.22% |
Revenue Growth (this year): | 1836.7% | Revenue Growth (next year): | -97.62% |
ADVM Breaking Stock News: Dive into ADVM Ticker-Specific Updates for Smart Investing
MT Newswires
2 months ago
GlobeNewswire
3 months ago
Yahoo Finance Video
3 months ago
Yahoo Finance
3 months ago
GlobeNewswire
3 months ago
GlobeNewswire
3 months ago
PR Newswire
3 months ago
CNW Group
3 months ago
The information presented on this page, "ADVM Adverum Biotechnologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.